Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, December 9 at 2:00 PM ET

Register Free →

Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)

Forecast
RFA-CA-28-004Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Cancer Institute is seeking applications through a limited competition Notice of Funding Opportunity to maintain two distinct biospecimen banking resources. The National Clinical Trials Network Biobanks support the NCTN and Community Oncology Research Program by collecting and distributing clinically annotated human biospecimens to facilitate biomarker development and secondary research. Simultaneously, the Early-Phase and Experimental Clinical Trials Biobank focuses on the needs of the ETCTN and other early-phase trials involving investigational new drugs to accelerate the development of effective cancer treatments. These resources aim to bridge basic science and clinical applications to enable translational cancer research regarding disease mechanisms and therapeutic responses. This current notice serves as a forecast to allow eligible organizations time to establish collaborations before the formal application process begins. Selected projects will undergo peer review and will be funded based on merit.

General Info

NCI funds continuation of biospecimen banks supporting cancer clinical and experimental trials.

Documents

0

No documents available

Documents will appear here when they are available.

AI Contract Breakdown

Uniform Contract Format

No documents to break down

The breakdown needs solicitation documents. None were found from this contract's source.

Get what you need to respond

No documents were posted with this contract.

  • Buyer contactEmail and phone
  • Original solicitationLink to the source posting
Get the buyer contact

Ask CLEATUS

I've read this contract. Ask me anything.

Timeline

PhaseForecast
Posted

forecast

Prepare for this forecast

Research the agency, track this forecast, and prepare your capture plan before the solicitation opens.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA

Full Description

Show more

Through this limited competition Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications to support continuation of the two distinct biospecimen banking resources:

  • The National Clinical Trials Network (NCTN) Biospecimen Banks (NCTN Biobanks) support the NCI-funded NCTN and the Community Oncology Research Program (NCORP), and
  • The Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) support the Experimental Therapeutics Clinical Trials Network (ETCTN) and NCI-supported other early phase and experimental clinical trials.

The objective is to maintain these robust national resources for continuing the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens. The goal of these resources is to ensure availability of biospecimens from participants in NCI-funded clinical trials focused on treatment, prevention, and cancer control studies to enable translational cancer research. NCTN Biobanks support the biobanking operations of the NCTN funded through the Cancer Therapy Evaluation Program (CTEP) and NCORP funded through the Division of Cancer Prevention (DCP). The clinical trials conducted through NCTN and NCORP enroll thousands of patients with adult and childhood cancers each year. NCTN Biobank operations aim to facilitate hypothesis-driven biomarker development and validation, secondary research studies, and broader scientific discovery. Biospecimens collected through harmonized protocols and long-term follow-up across large multi-site clinical trials provide valuable resources for studying disease mechanisms, therapeutic response, and clinical outcomes in different types of cancers.

This NOFO will also support the continuation of the EET Biobank, a dedicated resource with a primary focus on meeting the biospecimen banking needs of the ETCTN and other early-phase and experimental clinical trials involving investigational new drugs (INDs). Biospecimens collected from the early phase clinical trials enable validated biomarker assay development, pharmacokinetic and pharmacodynamic studies, investigation of drug action and resistance mechanisms, improved patient stratification, and broader scientific discovery. Unlike the NCTN Biobank, the EET Biobank bridges basic science and clinical applications that enable acceleration of NCI’s IND development efforts for effective cancer treatments. This is a forecast for a limited competition Notice of Funding Opportunity (NOFO) that will invite application(s) from eligible organizations to apply. Application(s) will be peer-reviewed and only funded if meritorious.

Applications are not being solicited at this time. Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.

Similar Contracts

Same NAICS industry code

NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute (NCI) has issued a Notice of Funding Opportunity (RFA-CA-28-004) for a limited competition to support the continuation of two critical biospecimen banking resources: the National Clinical Trials Network (NCTN) Biobanks and the Early-Phase and Experimental Clinical Trials (EET) Biobank. The primary objective is to maintain national resources for the collection, processing, storage, and distribution of clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the investigation of drug response and resistance mechanisms. The NCI intends to fund approximately six awards with a total program funding of $19 million for fiscal year 2027, with a maximum direct cost limit of $3.0 million per year and a requested project period of six years. Applications are evaluated based on scientific and technical merit through the NIH peer-review system, focusing on significance, environment, and the likelihood of the project to exert a sustained influence on the research field. Eligible organizations must maintain active SAM and eRA Commons registrations and provide specific documentation, including the current scale of operation, accomplishments, and standard operating procedures. Awardees are required to implement robust quality assurance programs, adhere to Federal Human Subjects Regulations under 45 CFR 46, and follow strict cybersecurity incident reporting protocols, including notifying the HHS within 48 hours of discovery. There is no set-aside status specified for this opportunity.
National Institutes Of Health

POSTED

about 1 month ago

DEADLINE

in 3 months
View Details
NAICS: 621991
Grant
Limited Competition: Biospecimen Banks to support NCI National Clinical Trials Network Biospecimen Banks (NCTN Biobanks) and the NCI Early-Phase and Experimental Clinical Trials Biospecimen Bank (EET Biobank) (U24 Clinical Trial Not Allowed)
Solicitation # RFA-CA-28-004
The National Cancer Institute is issuing a limited competition Notice of Funding Opportunity, solicitation RFA-CA-28-004, to support the continuation of two critical biospecimen banking resources. These resources include the National Clinical Trials Network Biobanks, which support the NCTN and the Community Oncology Research Program, and the Early-Phase and Experimental Clinical Trials Biospecimen Bank, which supports the ETCTN and other early-phase experimental trials. The primary objective is to maintain national infrastructure for the collection, processing, storage, and distribution of high-quality, clinically annotated human biospecimens to enable translational cancer research, biomarker development, and the study of drug response and resistance. Eligible organizations must submit applications by February 12, 2027, to be considered for funding. All submissions will undergo a standard NIH peer-review process, and only meritorious applications will be selected. These banks are essential for linking biospecimens to clinical outcome data from large multi-site trials and supporting the development of novel cancer therapies through pharmacokinetic and pharmacodynamic analyses.
National Cancer Institute

POSTED

about 1 month ago

DEADLINE

in 3 months
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

Earlier notices in this NAICS code

Posted before this notice, open and closed

Research this forecast and prepare for the solicitation

Every solicitation package arrives shredded into a compliance breakdown and matched to your past performance, with incumbent history and alerts on amendments and award.

Miguel
Hillary
Keith Deutsch
Christine

Join 900+ contractors already using CLEATUS